Exelixis’ Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. SPY
2. WBD
3. PSKY
4. NVDA
5. TSLA
6. USO
7. AMD
8. ACN
9. COHR
10. META

Go back to Exelixis’ Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma
Exelixis, Inc. (NASDAQ: EXEL) Delayed: 57.22 -1.14 (1.95%)
Previous Close $58.36    52 Week High $17.00 
Open $58.61    52 Week Low $3.55 
Day High $58.81    P/E N/A 
Day Low $56.90    EPS $-1.33 
Volume 2,102,597